MA32785B1 - Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine - Google Patents

Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine

Info

Publication number
MA32785B1
MA32785B1 MA33833A MA33833A MA32785B1 MA 32785 B1 MA32785 B1 MA 32785B1 MA 33833 A MA33833 A MA 33833A MA 33833 A MA33833 A MA 33833A MA 32785 B1 MA32785 B1 MA 32785B1
Authority
MA
Morocco
Prior art keywords
digigatran
etexilate
classical
salt
treating
Prior art date
Application number
MA33833A
Other languages
Arabic (ar)
English (en)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41463075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32785(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32785B1 publication Critical patent/MA32785B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

L'invention porte sur un procédé de prévention d'un accident vasculaire cérébral chez un patient souffrant d'une fibrillation auriculaire, le patient ne présentant aucun facteur de risque vis-à-vis d'évènements d'hémorragie majeurs, le procédé consistant à administrer au patient 150 mg d'étexilate de dabigatran deux fois par jour, éventuellement sous la forme d'un sel pharmaceutiquement acceptable de celui-ci.
MA33833A 2008-11-11 2011-05-11 Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine MA32785B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11341308P 2008-11-11 2008-11-11
US23755909P 2009-08-27 2009-08-27
PCT/EP2009/064874 WO2010055022A1 (fr) 2008-11-11 2009-11-10 Procédé de traitement ou de prévention de thrombose à l'aide d'étexilate de dabigatran ou d'un sel de celui-ci avec une efficacité accrue par rapport à une thérapie classique par warfarine

Publications (1)

Publication Number Publication Date
MA32785B1 true MA32785B1 (fr) 2011-11-01

Family

ID=41463075

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33833A MA32785B1 (fr) 2008-11-11 2011-05-11 Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine

Country Status (21)

Country Link
US (3) US20110269799A1 (fr)
EP (1) EP2355823A1 (fr)
JP (1) JP2013510073A (fr)
KR (1) KR20110082564A (fr)
CN (2) CN103463083A (fr)
AR (1) AR074107A1 (fr)
AU (1) AU2009315730A1 (fr)
BR (1) BRPI0921354A2 (fr)
CA (1) CA2738884A1 (fr)
CL (1) CL2011000806A1 (fr)
CO (1) CO6382133A2 (fr)
EA (1) EA201100755A1 (fr)
EC (1) ECSP11011029A (fr)
IL (1) IL211853A0 (fr)
MA (1) MA32785B1 (fr)
MX (1) MX2011004796A (fr)
NZ (1) NZ592615A (fr)
PE (1) PE20110432A1 (fr)
TN (1) TN2011000227A1 (fr)
TW (1) TW201031651A (fr)
WO (1) WO2010055022A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738883A1 (fr) 2008-11-11 2010-05-20 Boehringer Ingelheim International Gmbh Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique
LT2550966T (lt) * 2011-07-25 2017-01-25 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Dabigatrano amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų panaudojimas kaip vaistų
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
WO2015071841A1 (fr) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes de dabigatran et ses dérivés, procédé de préparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
CN108254216B (zh) * 2018-03-15 2021-04-27 攀钢集团西昌钢钒有限公司 一种高炉槽的矿料取样方法、装置及可读存储介质
US20220175748A1 (en) * 2019-03-06 2022-06-09 University Of Rochester Anticoagulant compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応

Also Published As

Publication number Publication date
AU2009315730A1 (en) 2010-05-20
TW201031651A (en) 2010-09-01
AR074107A1 (es) 2010-12-22
JP2013510073A (ja) 2013-03-21
CO6382133A2 (es) 2012-02-15
MX2011004796A (es) 2011-05-30
PE20110432A1 (es) 2011-07-16
EA201100755A1 (ru) 2011-12-30
ECSP11011029A (es) 2011-06-30
WO2010055022A1 (fr) 2010-05-20
US20120277269A1 (en) 2012-11-01
CA2738884A1 (fr) 2010-05-20
US20110269799A1 (en) 2011-11-03
NZ592615A (en) 2013-06-28
CL2011000806A1 (es) 2011-11-11
CN103463083A (zh) 2013-12-25
KR20110082564A (ko) 2011-07-19
EP2355823A1 (fr) 2011-08-17
BRPI0921354A2 (pt) 2019-09-24
US20100322870A1 (en) 2010-12-23
CN102209546A (zh) 2011-10-05
IL211853A0 (en) 2011-06-30
TN2011000227A1 (en) 2012-12-17

Similar Documents

Publication Publication Date Title
MA32785B1 (fr) Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine
MA32786B1 (fr) Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique
MY139689A (en) Imidazotriazines as protein kinase inhibitors
EA201101475A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
EA200970933A1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
TW200602048A (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
WO2013049770A3 (fr) Méthodes de traitement du cancer
NO20071243L (no) Substituterte biarylpiperazinylpyridinanaloger.
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
TN2015000529A1 (en) Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors
EA201101231A1 (ru) Способы предотвращения или снижения риска смертности
CR20210375A (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
TW200633692A (en) Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
WO2008016665A3 (fr) Composés et méthodes de traitement de troubles médiés par flt3
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
MX2022002993A (es) Rebamipida para usarse en la prevencion y/o tratamiento de la rigidez arterial.
UA105645C2 (uk) Застосування етексилату дабігатрану, необов'язково у формі фармацевтично прийнятної солі, для запобігання інсульту у пацієнта, що страждає від миготливої аритмії